The EU review has now concluded that Esmya may have contributed to the onset of some of the 8 cases of serious liver injury. A number of permanent measures have been recommended to minimise this risk – these replace the measures announced in February. 

In particular, liver function monitoring is to be carried out in all women treated with Esmya before, during, and after treatment. 

The full announcement can be found below.